|
1
|
Chan HSH, Chen CI and Reece DE: Current
review on high-risk multiple myeloma. Curr Hematol Malig Rep.
12:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weaver CJ and Tariman JD: Multiple myeloma
genomics: A systematic review. Semin Oncol Nurs. 33:237–253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rafei H, Haroun F and Tabbara IA: Novel
immunotherapeutic agents for the treatment of multiple myeloma. Am
J Clin Oncol. 42:317–329. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riccomi G, Fornaciari G and Giuffra V:
Multiple myeloma in paleopathology: A critical review. Int J
Paleopathol. 24:201–212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vo MC, Lakshmi TJ, Jung SH, Cho D, Park
HS, Chu TH, Lee HJ, Kim HJ, Kim SK and Lee JJ: Cellular
immunotherapy in multiple myeloma. Korean J Intern Med. 34:954–965.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, He L, Du Y, Zhu P, Huang G, Luo J,
Yan X, Ye B, Li C, Xia P, et al: The long noncoding RNA lncTCF7
promotes self-renewal of human liver cancer stem cells through
activation of Wnt signaling. Cell Stem Cell. 16:413–425. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu B, Chen M, Gao M, Cong Y, Jiang L, Wei
J and Huang J: Down-regulation of lncTCF7 inhibits cell migration
and invasion in colorectal cancer via inhibiting TCF7 expression.
Hum Cell. 32:31–40. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu J and Wang D: Long noncoding RNA TCF7
promotes invasiveness and self-renewal of human non-small cell lung
cancer cells. Hum Cell. 30:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li T, Zhu J, Wang X, Chen G, Sun L, Zuo S,
Zhang J, Chen S, Ma J, Yao Z, et al: Long non-coding RNA lncTCF7
activates the Wnt/β-catenin pathway to promote metastasis and
invasion in colorectal cancer. Oncol Lett. 14:7384–7390.
2017.PubMed/NCBI
|
|
11
|
Huls G, van Es J, Clevers H, de Haan G and
van Os R: Loss of Tcf7 diminishes hematopoietic stem/progenitor
cell function. Leukemia. 27:1613–1614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ludwig H, Miguel JS, Dimopoulos MA,
Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J,
Jurczyszyn A, et al: International Myeloma Working Group
recommendations for global myeloma care. Leukemia. 28:981–992.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anderson KC, Alsina M, Atanackovic D,
Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC,
Gasparetto C, Godby K, et al: Multiple myeloma, version 2.2016:
Clinical practice guidelines in oncology. J Natl Compr Canc Netw.
13:1398–1435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar S, Paiva B, Anderson KC, Durie B,
Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et
al: International myeloma working group consensus criteria for
response and minimal residual disease assessment in multiple
myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Z, Shu B, Xu Y, Liu J, Wang P, Chen
L, Zhao J, Liu X, Qi S, Xiong K, et al: microRNA-203 modulates
wound healing and scar formation via suppressing Hes1 expression in
epidermal stem cells. Cell Physiol Biochem. 49:2333–2347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duchaine TF and Fabian MR: Mechanistic
Insights into MicroRNA-Mediated gene silencing. Cold Spring Harb
Perspect Biol. 11:a0327712019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mihanfar A, Fattahi A and Nejabati HR:
MicroRNA-mediated drug resistance in ovarian cancer. J Cell
Physiol. 234:3180–3191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu SG, Chang TH, Liu YN and Shih JY:
MicroRNA in lung cancer metastasis. Cancers (Basel). 11:2652019.
View Article : Google Scholar
|
|
22
|
Wu SQ, Niu WY, Li YP, Huang HB and Zhan R:
miR-203 inhibits cell growth and regulates G1/S transition by
targeting Bmi-1 in myeloma cells. Mol Med Rep. 14:4795–4801. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia CM, Tian YY, Quan LN, Jiang L and Liu
AC: miR-26b-5p suppresses proliferation and promotes apoptosis in
multiple myeloma cells by targeting JAG1. Pathol Res Pract.
214:1388–1394. 2018. View Article : Google Scholar : PubMed/NCBI
|
